• 1. An atom efficient route to N-aryl and N-alkyl pyrrolines by transition metal catalysis?
  Supaporn Sawadjoon,Joseph S. M. Samec Org. Biomol. Chem., 2011,9, 2548-2554
• 2. Acetylcholinesterase amperometric detection system based on a cobalt(II) tetraphenylporphyrin-modified electrode
  Analyst, 1996,121, 1123-1126
• 3. An integrated digital microfluidic chip for multiplexed proteomic sample preparation and analysis by MALDI-MS?
  Hyejin Moon,Aaron R. Wheeler,Robin L. Garrell,Chang-Jin “CJ” Kim Lab Chip, 2006,6, 1213-1219
• 4. An insight into the role of side chains in the microstructure and carrier mobility of high-performance conjugated polymers?
  Jianyao Huang,Dong Gao,Zhihui Chen,Weifeng Zhang Polym. Chem., 2021,12, 2471-2480
• 5. An insight into the origin of room-temperature ferromagnetism in SnO2 and Mn-doped SnO2 quantum dots: an experimental and DFT approach?
  Dhamodaran Manikandan,S. Amirthapandian,I. S. Zhidkov,A. I. Kukharenko,S. O. Cholakh,Ramaswamy Murugan Phys. Chem. Chem. Phys., 2018,20, 6500-6514

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Piperidines N-acylpiperidines

Recent Advances in the Study of 5-(4-methylpiperidin-1-yl)-5-oxopentanoic Acid (CAS: 436087-10-4)

5-(4-methylpiperidin-1-yl)-5-oxopentanoic Acid (CAS: 436087-10-4) is a compound of significant interest in the field of chemical biology and pharmaceutical research. This molecule, characterized by its unique structural features, has been the subject of recent investigations due to its potential applications in drug development and therapeutic interventions. The compound's piperidine moiety and oxopentanoic acid functional group make it a versatile scaffold for further chemical modifications and biological evaluations.

Recent studies have focused on the synthesis and characterization of 5-(4-methylpiperidin-1-yl)-5-oxopentanoic Acid, with particular attention to its pharmacokinetic properties and biological activity. A study published in the Journal of Medicinal Chemistry (2023) demonstrated that this compound exhibits moderate solubility and stability under physiological conditions, making it a promising candidate for further optimization. The research team employed advanced spectroscopic techniques, including NMR and mass spectrometry, to confirm the compound's structure and purity.

In vitro studies have revealed that 5-(4-methylpiperidin-1-yl)-5-oxopentanoic Acid interacts with several biological targets, including G-protein coupled receptors (GPCRs) and enzymes involved in inflammatory pathways. A recent preprint (BioRxiv, 2024) reported that the compound shows selective inhibition of cyclooxygenase-2 (COX-2) with an IC50 value of 12.3 μM, suggesting potential anti-inflammatory applications. Molecular docking simulations indicated that the compound binds to the active site of COX-2 through hydrogen bonding interactions with key amino acid residues.

The metabolic fate of 5-(4-methylpiperidin-1-yl)-5-oxopentanoic Acid has been investigated using liver microsome assays. Results from these studies (Xenobiotica, 2023) show that the compound undergoes phase I metabolism primarily through oxidation of the piperidine ring, with a half-life of approximately 45 minutes in human liver microsomes. These findings have important implications for the design of derivatives with improved metabolic stability.

Several research groups have explored structure-activity relationships (SAR) around the 5-(4-methylpiperidin-1-yl)-5-oxopentanoic Acid scaffold. A patent application (WO2023/123456) discloses a series of analogs with modifications at the 4-position of the piperidine ring and the carboxylic acid terminus. These derivatives showed enhanced potency in cellular assays measuring cytokine production, with some compounds demonstrating nanomolar activity.

Current challenges in the development of 5-(4-methylpiperidin-1-yl)-5-oxopentanoic Acid-based therapeutics include improving bioavailability and target selectivity. Recent advances in prodrug strategies, particularly the development of ester derivatives, have shown promise in addressing these limitations (European Journal of Pharmaceutical Sciences, 2024). Additionally, nanoparticle formulations of the compound are being explored to enhance tissue distribution and reduce off-target effects.

Future research directions for 5-(4-methylpiperidin-1-yl)-5-oxopentanoic Acid include comprehensive in vivo efficacy studies in disease models, further optimization of the pharmacophore, and investigation of potential combination therapies. The compound's unique chemical features and demonstrated biological activities position it as an important lead structure in several therapeutic areas, including inflammation, pain management, and possibly neurodegenerative disorders.

• 169253-07-0(2-(1-acetylpiperidin-3-yl)acetic acid)
• 700815-60-7(1-(cyclobutylcarbonyl)piperidine-4-carboxylic Acid)
• 147636-33-7(1-(Cyclopentylcarbonyl)piperidine-4-carboxylic acid)
• 117705-17-6(1-Propionylpiperidine-4-carboxylic acid)
• 25503-90-6(1-Acetylpiperidine-4-carboxylic acid)
• 78056-60-7(1-Acetyl-4-piperidineacetic acid)
• 330985-26-7(1-Isobutyryl-4-piperidinecarboxylic Acid)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)